For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate...
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full...
Lung Cancer Video Library - Spanish Language: Video #36 Treatment Options for Acquired Resistance to EGFR TKIs: T790M-Negative Disease
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses treatment options for acquired resistance to EGFR TKIs: T790M-negative disease.
- 1 of 4
- View More
GRACE is excited to share with you a partnership with Lilly Oncology to provide you information that reflects our shared interests. We are happy to...
From the Grace Archives | Originally P ublished December 6, 2006 | By Dr West | 25 Comments Bronchioloalveolar carcinoma, or BAC , is a subtype of...
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".
- 1 of 9
- View More
My wife was on Tarceva for over 6 1/2 years. Then she developed acquired resistance to Tarceva with prevascular and supraclevical lymph nodes...